Rising levels of Annexin V-positive MVs during chemoradiation therapy correlated with earlier tumour recurrence and reduced overall survival.Patients with higher levels of MVs had >4-fold increase in the hazard ratio for recurrence compared to those with lower levels The study provided initial evidence that monitoring blood-borne MV levels could serve as a non-invasive method to predict disease progression and patient outcomes in newly diagnosed GBM patients. This evidence concerns the gene ANXA5 and glioblastoma.